Clinical trials: Cisplatin
Extensive-stage Small Cell Lung Cancer
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.
- Trial name
- LUMINANCE (NCT04774380)
- Testing
- Durvalumab, Cisplatin, Carboplatin
- Where
- 35 sites in Bulgaria, Canada and 4 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated Chinese adults with gastric and gastroesophageal…
- Trial name
- NCT04882241
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 20 sites in China
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Cancer
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer.
- Trial name
- EV-302 (NCT04223856)
- Testing
- Enfortumab vedotin, Pembrolizumab, Cisplatin
- Where
- 260 sites in United States, Argentina and 23 more
- Volunteers
- 886 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Small Cell Lung Carcinoma Extensive Disease
Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer
This is a Phase IIIb, interventional, single arm, multicentre study to evaluate safety, effectivenees, use of resources and patient reporting outcomes in patients with ES-SCLC treated with durvalumab in combination with…
- Trial name
- CANTABRICO (NCT04712903)
- Testing
- Durvalumab, Cisplatin, Etoposide
- Where
- 34 sites in Spain
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Carcinoma, Squamous Cell of Head and Neck
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head…
- Trial name
- CHANGE2 (NCT02383966)
- Testing
- Cetuximab, Cisplatin/Carboplatin, 5-fluorouracil
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Gastric Cancer
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
This randomized, multicenter, open-label study will evaluate two different doses of pertuzumab in combination with Herceptin (trastuzumab) and chemotherapy in the first-line treatment of participants with metastatic HER2-positive…
- Trial name
- JOSHUA (NCT01461057)
- Testing
- Capecitabine, Cisplatin, Pertuzumab
- Where
- 24 sites in Belgium, Czechia and 6 more
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Urothelial Carcinoma
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
- Trial name
- NCT01353222
- Testing
- DN24-02, Standard of Care
- Where
- 60 sites in United States
- Volunteers
- 142 people
- Sponsor
- Dendreon
Lung Cancer
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
This study is intended for participants with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy.
- Trial name
- NCT00538681
- Testing
- enzastaurin, pemetrexed, cisplatin
- Where
- 12 sites in Belgium, Germany and 3 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Transitional Cell Carcinoma of Bladder, Urethra Cancer
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who…
- Conditions
- Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
- Trial name
- NCT01326871
- Testing
- Cisplatin, Gemcitabine, ALT-801
- Where
- 16 sites in United States
- Volunteers
- 68 people
- Sponsor
- Altor BioScience
Non Small Cell Lung Cancer
Phase I Combination Ixabepilone + Cisplatin
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the…
- Trial name
- NCT00832117
- Testing
- Ixabepilone, Cisplatin
- Where
- 7 sites in United States, Italy
- Volunteers
- 30 people
- Sponsor
- R-Pharm
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with…
- Trial name
- HELOISE (NCT01450696)
- Testing
- Capecitabine, Cisplatin, Herceptin
- Where
- 117 sites in United States, Australia and 23 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Solid Tumor
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
- Trial name
- NCT02393248
- Testing
- Pemigatinib, Gemcitabine, Pembrolizumab
- Where
- 20 sites in United States, Denmark
- Volunteers
- 201 people
- Sponsor
- Incyte Corporation
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone.
- Trial name
- NCT01363479
- Testing
- Oral palonosetron, I.V. palonosetron, Dexamethasone
- Where
- 79 sites in United States, Argentina and 10 more
- Volunteers
- 743 people
- Sponsor
- Helsinn Healthcare SA
Mesothelioma
Nintedanib (BIBF 1120) in Mesothelioma
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin…
- Trial name
- NCT01907100
- Testing
- Nintedanib, Pemetrexed, Cisplatin
- Where
- 123 sites in United States, Argentina and 25 more
- Volunteers
- 545 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined.
- Trial name
- NCT00191854
- Testing
- gemcitabine, paclitaxel, carboplatin
- Where
- 18 sites in Brazil, China and 4 more
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Stomach Neoplasms
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.
- Trial name
- NCT00553696
- Testing
- Cisplatin, S-1, Sunitinib
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Pfizer
Head and Neck Cancer
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer.
- Trial name
- NCT00122460
- Testing
- Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU), Platinum (Cisplatin or Carboplatin) + 5-FU
- Where
- 70 sites in Austria, Belgium and 15 more
- Volunteers
- 442 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non-Squamous Non-Small Cell Lung Cancer
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer.
- Trial name
- NCT00961415
- Testing
- bevacizumab [Avastin], cisplatin, pemetrexed
- Where
- 91 sites in France, Germany and 10 more
- Volunteers
- 376 people
- Sponsor
- Hoffmann-La Roche
Neoplasm, Gastric
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
This is a multicenter, single arm, open-label Phase 1/2 study of pemetrexed plus cisplatin for patients with unresectable, advanced gastric cancer who had no prior palliative chemotherapy.
- Trial name
- NCT00320515
- Testing
- pemetrexed, cisplatin
- Where
- 8 sites in Argentina, Mexico and 2 more
- Volunteers
- 89 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer (SCLC)
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum [EP]) in participants with newly diagnosed extensive stage small cell lung cancer…
- Trial name
- NCT03066778
- Testing
- Pembrolizumab, Normal saline solution, Carboplatin
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC